查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011181

栓塞治疗市场：按产品类型、应用和最终用户分類的全球市场预测 - 2026-2032 年

Embolotherapy Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，栓塞疗法市场价值将达到 52.2 亿美元，到 2026 年将成长至 56.8 亿美元，到 2032 年将达到 96.7 亿美元，复合年增长率为 9.19%。

主要市场统计数据
基准年 2025 52.2亿美元
预计年份：2026年 56.8亿美元
预测年份 2032 96.7亿美元
复合年增长率 (%) 9.19%

这本入门书籍重点介绍了栓塞疗法的发展历程、临床应用趋势、器械进步以及对塑造现代治疗实践的相关人员的影响。

栓塞治疗已从一项小众介入技术发展成为多个临床专科的核心治疗方法手段，这得益于器械创新、适应症拓展以及临床医生技术水平的提升。过去十年，栓塞材料和输送系统的技术改进提高了手术精准度、止血效果和病灶长期管理水准。同时，介入性放射科、神经外科、血管外科和肿瘤科之间日益密切的跨学科合作，拓宽了治疗范围，并促进了最佳实践的共用。

材料科学的突破、与诊断影像的整合、程序工作流程以及监管重点如何全面重塑栓塞治疗的实践和行业方向。

栓塞治疗的现状正因多项变革性变化而重塑，这些变化正在影响临床决策、产品开发和医疗保健系统规划。首先，材料科学的创新催生了具有可预测降解特性、增强的渗透性和可调式闭塞性能的栓塞器。这些进步正在改变实验室中的器械选择演算法，从而减少脱靶效应并实现更精准的治疗。

美国近期关税措施对采购、供应链韧性、製造策略和临床设备供应的实际影响。

2025年实施的关税政策为美国医疗保健体系内栓塞器械和耗材的采购和供应链带来了显着的复杂性。进口关税及相关合规要求提高了某些进口零件和成品的总成本，迫使医疗机构和製造商重新评估筹资策略和供应商多元化。为此，采购团队正在加强对整体拥有成本（TCO）的审查，不仅考虑单价，还考虑物流、前置作业时间和库存持有成本。

栓塞治疗产品类型，适应症范围广泛，涵盖神经血管治疗到子宫治疗，以及不同临床环境下的特定临床、手术和采购趋势。

详细的細項分析揭示了产品类型、临床应用和终端用户环境等方面的微妙部署模式，这些模式共同有助于商业化和临床策略的发展。在考虑产品类型时，临床医生和采购团队需要权衡临时性闭塞工具（如球囊）和长期性闭塞装置（如弹簧圈）之间的优点和缺点。同时，液体栓塞剂和颗粒栓塞剂具有不同的药物动力学和操作特性，这会影响它们在肿瘤治疗和血管畸形管理中的选择。栓塞器在需要快速局部闭塞的特殊手术中也发挥着至关重要的作用。每种产品类型都面临着独特的操作、储存和临床医生培训方面的挑战，这些挑战会影响药物的选择决策和手术管理能力。

临床基础设施、监管途径和供应链的地域差异如何影响美洲、欧洲、中东和非洲以及亚太地区栓塞疗法的引入？

区域趋势对临床应用、报销途径、监管合规和供应链物流有显着影响，美洲、欧洲、中东和非洲以及亚太地区呈现出不同的特征。在美洲，先进的介入治疗基础设施和整合卓越临床水平的中心正在推动复杂手术和高科技栓塞平台的快速普及。同时，支付方模式也越来越重视以价值主导的治疗结果和成本效益分析，这影响着器械选择和手术核准流程。这种环境有利于那些拥有可靠临床证据和高效供应链的产品。

领先的综合医疗设备製造商、专家创新者和供应链合作伙伴采取策略行动，推动栓塞治疗领域的商业化、证据产生和业务拓展。

栓塞治疗领域企业的策略体现了平台广度、专业化和合作伙伴关係之间的平衡，以加速临床检验和分销网络的拓展。成熟的医疗设备製造商倾向于透过整合输送系统、影像辅助配件和各种栓塞伙伴关係，提供端到端的手术解决方案，从而吸引大规模医院系统和综合医疗网路。这些企业通常会投资于广泛的培训计画、与关键意见领袖 (KOL) 的合作以及多中心临床试验，以证明其产品在不同适应症中的疗效。

针对医疗设备製造商、医疗保健系统和经销商的具体策略行动，以加强证据、供应链弹性、临床医生培训和适应性经营模式。

行业领导企业应根据​​不断变化的环境调整其商业和临床策略，优先投资于能够带来显着临床价值和提升信誉度的项目。首先，企业需要加快创建严谨的临床和真实世界证据，以解答支付方的关键问题，并促进多学科团队的协作。将栓塞特性与病患预后连结的转化研究将有助于强化产品定位，并促进医保报销的讨论。

结合临床文献综述、监管分析、专家访谈和三角验证整合的调查方法，可以得出可靠且可操作的见解。

本执行摘要的研究整合了同行评审的临床文献、监管文件、操作指南以及对临床医生、采购经理和行业专家的匿名访谈。关键的定性资料是透过半结构式访谈收集的，旨在了解医疗设备选择、流程和供应趋势方面的实践经验；而二手资料则提供了关于技术创新、监管趋势和支付方观点的背景资讯。数据三角验证证实，临床观察结果在应用前已获得监管和商业性证据的支持。

简明扼要地整合了临床进展、操作挑战和策略因素，这些因素全面决定了栓塞治疗的成功和有效性。

总之，栓塞术在现代介入医学中发挥着至关重要的作用，这得益于栓塞材料的进步、与影像诊断技术的融合以及多学科临床路径的建构。由于器材创新、医疗机构的采纳模式以及不断变化的支付方期望之间存在相互作用，因此，采取综合方法对于栓塞术的商业化和临床应用至关重要。相关人员必须权衡栓塞术方案的技术特性、终端用户环境中的实际操作情况以及影响器械供应的监管和政策环境。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 栓塞治疗市场：依产品类型划分

  • 气球
  • 线圈
  • 液态栓塞剂
  • 颗粒栓塞
  • 插头

第九章 栓塞治疗市场：依应用领域划分

  • 神经血管栓塞术
    • 动静脉畸形
    • 脑动脉瘤
    • 肿瘤栓塞术
  • 週边栓塞治疗
    • 週边动脉栓塞术
    • 週边静脉栓塞术
  • 摄护腺动脉栓塞术
  • 经动脉化疗栓塞术
  • 经动脉放射性栓塞术
  • 子宫肌瘤栓塞术

第十章 栓塞治疗市场：依最终使用者划分

  • 门诊手术中心
  • 医院
  • 专科诊所
    • 肿瘤中心
    • 血管中心

第十一章 栓塞治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 栓塞治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 栓塞治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国栓塞治疗市场

第十五章：中国栓塞治疗市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Artio Medical Inc.
  • B. Braun Melsungen AG
  • Balt Extrusion SA
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Medical LLC
  • Embolx Inc.
  • EndoShape Inc.
  • Guerbet SA
  • Instylla Inc.
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic plc
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Penumbra Inc.
  • QT Vascular Ltd.
  • Shape Memory Medical Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Surefire Medical Inc.
  • Terumo Corporation
  • TriSalus Life Sciences Inc.
  • Vascular Solutions Inc.
Product Code: MRR-4308E1C8878D

The Embolotherapy Market was valued at USD 5.22 billion in 2025 and is projected to grow to USD 5.68 billion in 2026, with a CAGR of 9.19%, reaching USD 9.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.22 billion
Estimated Year [2026] USD 5.68 billion
Forecast Year [2032] USD 9.67 billion
CAGR (%) 9.19%

A focused primer on embolotherapy evolution, clinical adoption trends, device advances, and stakeholder implications shaping contemporary therapeutic practice

Embolotherapy has transitioned from a niche interventional technique to a core modality across multiple clinical specialties, driven by device innovation, expanding procedural indications, and evolving clinician expertise. Over the past decade, technological refinements in embolic materials and delivery systems have improved procedural precision, hemostasis control, and long-term lesion management. At the same time, growing cross-disciplinary collaboration between interventional radiology, neurosurgery, vascular surgery, and oncology has broadened therapeutic applications and encouraged shared best practices.

Clinicians now leverage embolotherapy for a wide range of targets, from neurovascular anomalies and intracranial aneurysms to peripheral hemorrhage control, targeted oncologic embolization, and uterine-sparing fibroid therapy. These clinical expansions are supported by iterative improvements in imaging guidance, catheter platforms, embolic chemistries, and delivery techniques that reduce procedural times and complication rates. Consequently, institutional adoption has shifted from isolated centers of excellence toward a more mainstream integration within tertiary hospitals and specialty clinics.

Alongside clinical drivers, payer perspectives and procedural pathways are evolving, emphasizing value-based outcomes and minimally invasive alternatives to open surgery. As a result, stakeholders across procurement, product development, and clinical leadership must re-evaluate capital allocation, training priorities, and device selection criteria to maintain competitive advantage and deliver measurable patient benefit.

How material science breakthroughs, imaging integration, procedural workflows, and regulatory emphasis are collectively reshaping embolotherapy practice and industry direction

The landscape of embolotherapy is being redefined by several transformative shifts that influence clinical decision-making, product development, and health system planning. First, material science innovations have introduced embolic agents with predictable degradation profiles, enhanced radiopacity, and tunable occlusion characteristics. These advances reduce off-target effects and allow for increasingly targeted therapies, thus altering device selection algorithms in procedural suites.

Second, the integration of high-resolution imaging and real-time navigation tools has improved procedural accuracy and expanded candidate eligibility for complex interventions. As imaging-guided workflows mature, operators can execute more complex embolizations with lower complication rates, which in turn encourages broader clinical referral patterns. Third, convergence between oncologic therapy and interventional modalities has accelerated the adoption of locoregional treatments, such as transarterial approaches, by multidisciplinary tumor boards prioritizing organ preservation and combination regimens.

Furthermore, supply chain resilience and regulatory scrutiny are prompting manufacturers to invest in scalable manufacturing and comprehensive post-market surveillance. These strategic pivots are facilitating faster iteration cycles for next-generation embolics and delivery systems. Taken together, these shifts create a dynamic environment where clinical value, regulatory compliance, and manufacturing robustness are equally important determinants of long-term success.

Practical implications of recent United States tariff measures on procurement, supply chain resilience, manufacturing strategies, and clinical device availability

Tariff policies enacted in 2025 have introduced notable complexities across the procurement and supply chain for embolotherapy devices and consumables within the United States healthcare ecosystem. Import duties and associated compliance requirements have translated into increased landed costs for certain imported components and finished devices, prompting health systems and manufacturers to reassess sourcing strategies and supplier diversification. In response, procurement teams have increased scrutiny of total cost of ownership, factoring in not only unit price but also logistics, lead times, and inventory carrying costs.

Manufacturers are reacting through a combination of strategic responses that include re-negotiating supplier contracts, relocating certain manufacturing steps closer to demand centers, and qualifying alternate raw material sources to mitigate exposure to tariff-driven price volatility. These adjustments have downstream implications for product availability and the cadence of new product introductions, particularly for smaller specialized suppliers that may lack the scale to absorb incremental tariff-related costs.

Clinicians and hospital administrators are adapting by prioritizing procedural pathways where device choice does not materially affect clinical outcomes, thereby reducing immediate budgetary pressures. At the same time, value analyses and contract negotiations are becoming more granular, often involving scenario planning to anticipate future policy shifts. Consequently, tariff dynamics are accelerating strategic conversations about near-shore manufacturing, inventory resilience, and long-term supplier partnerships.

Segment-specific clinical, procedural, and procurement dynamics across embolic product categories, applications spanning neurovascular to uterine therapies, and diverse clinical settings

Detailed segmentation analysis reveals nuanced adoption patterns across product types, clinical applications, and end user settings that collectively inform commercialization and clinical strategies. When considering product type, clinicians and purchasing teams weigh trade-offs between temporary occlusion tools like balloons and long-term occlusive devices such as coils, while liquid embolics and particle embolics offer distinct pharmacokinetic and handling profiles that influence selection for tumor-directed therapies or vascular malformation management; plugs serve niche procedural roles where rapid, focal occlusion is required. Each product category carries unique handling, storage, and clinician training implications that affect formulary decisions and procedural throughput.

Application-specific dynamics further shape clinical pathways. In neurovascular embolization, procedural planning varies by indication: arteriovenous malformation management demands intricate nidus access and durable vessel occlusion, cerebral aneurysm treatment emphasizes flow diversion and neck preservation, and tumor embolization balances ischemic effect with surrounding tissue preservation. Peripheral embolization differentiates between arterial and venous targets, each presenting distinct access challenges and embolic agent preferences. Prostate artery embolization requires fine microcatheter navigation and precise particle selection to minimize non-target ischemia, whereas transarterial chemoembolization and transarterial radioembolization integrate locoregional drug or radionuclide delivery with embolic occlusion. Uterine fibroid embolization prioritizes uterine artery embolic agents and techniques that maximize symptom relief while preserving reproductive considerations.

End user settings also influence pathway design and economic calculus. Ambulatory surgical centers emphasize throughput, standardized device kits, and rapid turnover, which favor modular, easy-to-deploy embolic systems. Hospitals offer broader clinical complexity and multidisciplinary support for hybrid procedures and high-acuity cases, enabling adoption of advanced embolic chemistries and multi-device strategies. Specialty clinics, including oncology centers and vascular centers, concentrate procedural volumes in specific indications and can invest in targeted clinician training and device inventories that optimize outcomes for their patient cohorts. These segmentation insights emphasize that successful market engagement requires device portfolios and commercial models tailored to the procedural profile, clinician workflow, and institutional priorities of each segment.

How geographic heterogeneity in clinical infrastructure, regulatory pathways, and supply chains shapes embolotherapy adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a profound influence on clinical adoption, reimbursement pathways, regulatory navigation, and supply chain logistics, with distinct characteristics observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, advanced interventional infrastructure and concentrated centers of clinical excellence support rapid adoption of complex procedures and high-tech embolic platforms, while payer models increasingly focus on value-driven outcomes and cost-effectiveness analyses that influence device selection and procedural authorization processes. This environment favors products with robust clinical evidence and streamlined supply arrangements.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare funding create a mosaic of adoption rates. High-income European markets prioritize health technology assessments and real-world evidence to inform reimbursement, whereas emerging markets within the region face constraints related to capital procurement and device availability, prompting interest in cost-effective, easy-to-deploy solutions that address acute needs. Meanwhile, the Middle East and select African markets display targeted investment in specialist centers, enabling pockets of advanced practice.

Asia-Pacific presents a mix of rapid capacity expansion, increasing local manufacturing, and growing clinical expertise in interventional procedures. Several countries in this region are investing in training programs and imaging infrastructure, which accelerates the uptake of minimally invasive therapies. Additionally, regional manufacturing growth can shorten supply chains and create competitive pricing pressures, while diverse regulatory timelines necessitate tailored market entry strategies. Across all regions, localized regulatory requirements, clinician training pathways, and procurement cycles must inform commercialization planning and evidence generation strategies.

Strategic behaviors of large integrated device firms, specialized innovators, and supply chain partners that drive commercialization, evidence generation, and scaling across embolotherapy

Corporate strategies among companies active in embolotherapy reflect a balance between platform breadth, specialization, and partnerships that accelerate clinical validation and distribution reach. Established medical device firms tend to leverage integrated portfolios that combine delivery systems, imaging-compatible accessories, and a range of embolic chemistries to provide end-to-end procedural solutions, thereby appealing to large hospital systems and integrated care networks. These firms often invest in broad training programs, key opinion leader engagement, and multi-center clinical studies to substantiate comparative performance across indications.

At the same time, specialized developers and smaller innovators concentrate on differentiated embolic materials or niche delivery technologies, targeting specific indications such as neurovascular malformations or targeted oncologic embolization. Their agility allows for faster iteration cycles and the pursuit of advanced material science innovations, but commercial scaling frequently depends on strategic alliances with larger distributors or contract manufacturing organizations to expand geographic footprint and meet regulatory compliance demands.

In addition, contract manufacturers and component suppliers play a crucial role by enabling scalable production and ensuring supply chain continuity. Distribution partners and regional service organizations augment market reach and provide critical clinician training and device replenishment services. Collectively, company-level strategies are converging around evidence generation, supply chain resilience, clinician education, and selective portfolio expansion to capture clinical opportunities while managing regulatory and procurement complexities.

Concrete strategic actions for device manufacturers, health systems, and distributors to strengthen evidence, supply resilience, clinician training, and adaptive commercial models

Industry leaders should align commercial and clinical strategies to the evolving landscape by prioritizing investments that deliver demonstrable clinical value and supply reliability. First, companies should accelerate generation of rigorous clinical and real-world evidence that addresses key payer questions and supports adoption across multidisciplinary teams. Translational research that connects embolic properties to patient outcomes will strengthen product positioning and facilitate reimbursement conversations.

Second, enhancing manufacturing and sourcing resilience through supplier diversification, near-shoring, or dual-sourcing strategies will reduce exposure to policy-driven cost fluctuations and logistical disruptions. These operational changes should be complemented by proactive inventory management and demand forecasting tools to preserve procedural continuity. Third, targeted clinician education and accreditation programs will expand procedural competency beyond centers of excellence, enabling broader adoption in hospitals and specialty clinics while reducing procedural variability.

Fourth, commercial models must adapt to the procurement preferences of different end users by offering flexible kit configurations, subscription or consignment arrangements, and service-level agreements that include training and outcomes monitoring. Finally, strategic partnerships - whether through distribution agreements, co-development, or licensing - can accelerate geographic expansion and provide smaller innovators with the necessary scale to bring differentiated technologies to broader patient populations. Taken together, these actions will help firms convert technological promise into sustainable clinical and commercial outcomes.

Methodological approach combining clinical literature review, regulatory analysis, expert interviews, and triangulated synthesis to derive robust, actionable insights

The research underpinning this executive summary synthesizes peer-reviewed clinical literature, regulatory documentation, procedural guidelines, and anonymized interviews with clinicians, procurement leaders, and industry experts. Primary qualitative inputs were gathered through semi-structured interviews designed to capture practical experiences across device selection, procedural workflow, and supply dynamics, while secondary sources provided context on technological innovation, regulatory trends, and payer perspectives. Data triangulation ensured that clinical observations were corroborated with regulatory and commercial evidence before inclusion.

Analytical methods prioritized thematic synthesis and cross-segmentation comparisons to reveal adoption drivers and bottlenecks across product types, applications, and end user environments. Regional analyses integrated publicly available regulatory timelines and health system capacity indicators to identify differential adoption patterns. Wherever possible, validation rounds with subject matter experts refined interpretations and identified priority areas for further investigation. Limitations were acknowledged explicitly, including variability in regional reporting standards and the evolving nature of device registries and real-world datasets. This transparent approach ensures the conclusions remain actionable and grounded in multiple independent evidence streams.

A concise synthesis of clinical advances, operational challenges, and strategic levers that collectively determine successful adoption and impact of embolotherapy

In summary, embolotherapy occupies a pivotal role in contemporary interventional care, supported by advances in embolic materials, imaging integration, and multidisciplinary clinical pathways. The interplay between device innovation, institutional adoption patterns, and evolving payer expectations necessitates a holistic approach to commercialization and clinical deployment. Stakeholders must reconcile the technical attributes of embolic options with the operational realities of end user settings and the regulatory and policy environments that govern device availability.

Moreover, tariff-related policy changes and supply chain vulnerabilities emphasize the need for proactive sourcing strategies and flexible commercial models. Regional heterogeneity calls for tailored market entry and clinician engagement plans, while segmentation insights underscore the importance of indication-specific evidence and training. By focusing on evidence generation, supply security, clinician competency, and adaptable commercialization approaches, stakeholders can translate technological advances into improved patient outcomes and sustainable clinical programs.

Ultimately, success in this domain will depend on the ability to integrate clinical efficacy, operational reliability, and value-focused communication to payers and providers, enabling broader adoption of embolotherapy across the full spectrum of applicable indications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Embolotherapy Market, by Product Type

  • 8.1. Balloons
  • 8.2. Coils
  • 8.3. Liquid Embolics
  • 8.4. Particle Embolics
  • 8.5. Plugs

9. Embolotherapy Market, by Application

  • 9.1. Neurovascular Embolization
    • 9.1.1. Arteriovenous Malformation
    • 9.1.2. Cerebral Aneurysm
    • 9.1.3. Tumor Embolization
  • 9.2. Peripheral Embolization
    • 9.2.1. Peripheral Arterial Embolization
    • 9.2.2. Peripheral Venous Embolization
  • 9.3. Prostate Artery Embolization
  • 9.4. Transarterial Chemoembolization
  • 9.5. Transarterial Radioembolization
  • 9.6. Uterine Fibroid Embolization

10. Embolotherapy Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics
    • 10.3.1. Oncology Centers
    • 10.3.2. Vascular Centers

11. Embolotherapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Embolotherapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Embolotherapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Embolotherapy Market

15. China Embolotherapy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Artio Medical Inc.
  • 16.7. B. Braun Melsungen AG
  • 16.8. Balt Extrusion SA
  • 16.9. Boston Scientific Corporation
  • 16.10. Cardinal Health Inc.
  • 16.11. Cook Medical LLC
  • 16.12. Embolx Inc.
  • 16.13. EndoShape Inc.
  • 16.14. Guerbet SA
  • 16.15. Instylla Inc.
  • 16.16. Johnson & Johnson
  • 16.17. Kaneka Corporation
  • 16.18. Medtronic plc
  • 16.19. Medtronic plc
  • 16.20. Merit Medical Systems Inc.
  • 16.21. Penumbra Inc.
  • 16.22. QT Vascular Ltd.
  • 16.23. Shape Memory Medical Inc.
  • 16.24. Sirtex Medical Limited
  • 16.25. Stryker Corporation
  • 16.26. Surefire Medical Inc.
  • 16.27. Terumo Corporation
  • 16.28. TriSalus Life Sciences Inc.
  • 16.29. Vascular Solutions Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EMBOLOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EMBOLOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PARTICLE EMBOLICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PARTICLE EMBOLICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PARTICLE EMBOLICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PLUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PLUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PLUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CEREBRAL ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CEREBRAL ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CEREBRAL ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TUMOR EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TUMOR EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TUMOR EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL ARTERIAL EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL ARTERIAL EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL ARTERIAL EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL VENOUS EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL VENOUS EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL VENOUS EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TRANSARTERIAL CHEMOEMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TRANSARTERIAL CHEMOEMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TRANSARTERIAL CHEMOEMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TRANSARTERIAL RADIOEMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TRANSARTERIAL RADIOEMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY TRANSARTERIAL RADIOEMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY VASCULAR CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY VASCULAR CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY VASCULAR CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS EMBOLOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA EMBOLOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. GCC EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. G7 EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 164. NATO EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA EMBOLOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA EMBOLOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA EMBOLOTHERAPY MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA EMBOLOTHERAPY MARKET SIZE, BY PERIPHERAL EMBOLIZATION, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA EMBOLOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)